buyModerate

Timothy P Lynch bought $243k of AEON

owner at AEON Biopharma, Inc.. 1,150,000 shares at an average of $0.21, traded Aug 19, 2026, filed Aug 21, 2026.

Conviction score

Value

$243k

1,150,000 shares

Holdings after

6,500,000

+21% from before

From 52-week low

low $0.20, close $0.20

From 52-week high

-86%

high $1.40, as of Aug 19, 2026

Score components

Role
10% owner
+12
Trade size
$243k at market
+13
Relative to holdings
Holdings up 21%
+6
Price context
0% above the 52-week low; 86% below the 52-week high
+18
Cluster
No other insider buying within 14 days
0
Repeat buying
First buy in 90 days
0
Track record
Too few past buys to judge (0 with prices)
0
Outside holder
A 10% owner who is not an officer or director
-5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

AEONOct 12, 2026 · close 0.25

Since filing Aug 21, 2026: +28.1%SPY +1.9% · excess +26.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000935836-26-000440, as filed. Open on EDGAR

Date	Transaction	Shares	Price	Value	Holdings after	Filed
Aug 19, 2026	POpen-market purchase Class A Common Stock	+1,150,000	$0.21	$243k	6,500,000	Aug 21, 2026

Related signals

Other insiders at AEON Biopharma, Inc. and this insider’s other filings.

Score	Company	Insider	Value	Holdings	Filed
31Weak	AEONbuy AEON Biopharma, Inc.	Jost Fischer director	$29k 60,000 shares	+29%	May 23, 2025
32Weak	AEONbuy AEON Biopharma, Inc.	Jost Fischer director	$55k 110,000 shares	+114%	May 21, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.